Log in to your Inderes Free account to see all free content on this page.

Zelluna

Less than 1K followers

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

12.2.

2026

Annual report '25

All

Press releases

3rd party

ShowingAll content types

Regulatory press release11/28/2025, 6:50 AM

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer

Regulatory press release11/27/2025, 7:35 AM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/27/2025, 7:35 AM

Zelluna ASA: Disclosure of large shareholding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/25/2025, 3:05 PM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/25/2025, 11:09 AM

ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING

Regulatory press release11/25/2025, 10:32 AM

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Regulatory press release11/17/2025, 9:33 AM

Zelluna ASA: New share capital registered

Regulatory press release11/4/2025, 12:04 PM

Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025

Regulatory press release11/4/2025, 8:10 AM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/4/2025, 8:10 AM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/4/2025, 7:28 AM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/4/2025, 6:29 AM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/4/2025, 6:29 AM

Zelluna ASA: Disclosure of large shareholding

Regulatory press release11/4/2025, 6:00 AM

Zelluna ASA – Ex. date

Regulatory press release11/3/2025, 11:58 PM

Zelluna ASA – Key information relating to subsequent offering

Regulatory press release11/3/2025, 11:35 PM

Zelluna ASA - Mandatory notification of trade

Regulatory press release11/3/2025, 10:52 PM

Zelluna ASA - Successful private placement and retail offering

Regulatory press release11/3/2025, 3:47 PM

Zelluna ASA – Contemplates private placement

Regulatory press release11/3/2025, 3:39 PM

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update

Regulatory press release10/9/2025, 5:58 AM

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.